Background/Aims: Macrophage inflammatory protein-2 (MIP-2), a type of leukocyte chemokine, is primarily produced by macrophages, and levels increase significantly in early inflammation. However, the precise biological functions and mechanisms of MIP-2 in the development of inflammation remain unclear. The purposes of the present study were to investigate the role of MIP-2 in inflammation induced by lipopolysaccharide (LPS) in vitro and to determine the possibility of blocking the high mobility group box 1 (HMGB1) signalling pathway via MIP-2 inhibition. Methods: Macrophage cells (RAW264.7, U937 and THP-1 cells) were divided into control and treatments groups. Expression levels of interleukin-6 (IL-6), interleukin-1β (IL-1β), tumour necrosis factor-α (TNF-α), HMGB1, chemokine (C-C motif) ligand-2 (Ccl-2), Toll-like receptor-4 (TLR-4), inducible nitric oxide synthase (iNOS), phosphorylated MAPKs (p38, ERKs, JNKs), PI3K/Akts, JAKs/STAT3, IκB, and cytoplasmic and nuclear NF-κB p65 in RAW264.7 cells were detected by qRT-PCR, enzyme-linked immunosorbent assay (ELISA) or western blot assays. Results: mip-2 siRNA and an anti-MIP-2 antibody significantly reduced the expression levels of Ccl-2, TLR-4, iNOS, IL-6, IL-1β, HMGB1, and TNF-α in RAW264.7 cells exposed to LPS (P<0.01). Additionally, mRNA expression levels of HMGB1 and TLR-4 in cells treated with LPS+mip-2 siRNA were significantly lower than those in cells treated with LPS alone (P<0.01 or P<0.05). The MIP-2 antibody significantly suppressed activation of p38-MAPK, p-STAT3, and p-Akts and translocation of NF-κB p65 from the cytoplasm to the nucleus in RAW264.7 exposed to LPS (P<0.01 or P<0.05). Conclusion: mip-2 siRNA and the MIP-2 antibody can reduce the inflammatory effects induced by LPS in macrophage cells. The mechanisms may occur through down-regulation of p38-MAPK, STAT3 and Akts phosphorylation and translocation of NF-κB p65. MIP-2 plays an important role in inflammation induced by LPS.
Introduction
Lipopolysaccharide (LPS), a pathogen-associated molecular pattern (PAMP), can trigger a cascade of inflammatory processes. Binding of LPS to Toll-like receptor 4 (TLR-4) on macrophages initiates signalling that leads to more intricate biological responses, including the secretion of a number of pro-inflammatory mediators, and disturbs normal body function, resulting in liver injury, infarction, cardiovascular diseases, neurodegenerative disorders or even death [1] [2] [3] [4] [5] [6] [7] .
MIP-2, a member of the CXC chemokine family, is a peptide derived from monocytes/ macrophages, and can recruit neutrophils to infection sites [8] . Members of the chemokine family with the ability to mediate leukocyte chemotaxis can be classified into four subgroups according to the location of a cysteine in the polypeptide chain: C, CC, CXC, and CX3C [9, 10] . To date, at least 50 chemokines that exhibit various physiological and pathological properties have been identified, most of which belong to the CC and CXC subgroups [11] . Migration of neutrophils is primarily mediated by MIP-2, and Hu, B. and Devalaraja, et al. observed inhibition of neutrophil migration in response to LPS in CXCR2-knockout mice and in mice with CXCR2 specifically blocked by an antagonist [12, 13] . Thus, MIP-2 release has an important impact on the development of early immune responses. MIP-2 is mainly produced by macrophages, one of the most dominant and widely distributed inflammatory cells, and is involved in the initiation and maintenance of the acute inflammatory response [14] . Indeed, macrophages are central players in inflammation and the immune response; when exposed to LPS, TLR-4 on macrophages recognizes LPS and causes cell activation, including the production of NO and pro-inflammatory cytokines such as TNF-α and IL-6 [12, 15] .
HMGB1 is constitutively expressed in quiescent macrophages/monocytes, stored in the nucleus, actively secreted from stimulated macrophages, and passively released from injured cells. HMGB1 was originally recognized as an intranuclear protein that functions in the maintenance of nucleosome structure, chromatin remodelling, and the regulation of gene transcription [16] . In addition, extracellular HMGB1 can play a critical role in the pathogenesis of inflammation with or without infection. Extracellular HMGB1 under various pathologic states is largely derived from a passive release pathway related to the death and decomposition of cells or an active pathway in live cells such as macrophages/monocytes [17] [18] [19] . HMGB1 is a DNA-binding protein that possesses cytokine-like, pro-inflammatory properties. Cell surface receptors that engage in HMGB1 interaction include RAGE, TLR-4 and TLR-2. Macrophage activation by HMGB1 results in cytokine secretion; when released into the extracellular milieu, HMGB1, as a potent pro-inflammatory cytokine, activates a wide range of inflammatory responses, including massive production of chemokine adhesion molecules (e.g., ICAM-1, VCAM-1) and cytokines (e.g., TNF-α, IL-1β, NO) [16, 17, 20, 21] . In recent years, some experimental and clinical data have highlighted the contributions of extracellular HMGB1 to the pathogenesis of many inflammatory and cancer diseases.
Kollmar, O., et al. previously reported that antibody neutralization of MIP-2 or KC significantly reduced the levels of these pro-inflammatory cytokines in liver tissue and influx of neutrophils to the liver [22] . However, it remains unclear whether MIP-2 has an effect on HMGB1 secretion in RAW264.7 cells. Moreover, Zhou, H., et al. previously demonstrated that Gu-4 significantly attenuated the HMGB1 mRNA expression levels in RAW264.7 cells exposed to LPS, which promotes the aggravation of inflammation [23] . It was assumed that MIP-2 critically contributes to HMGB1 release; thus, it is necessary to conduct experiments to determine whether inhibition of MIP-2 secretion by silencing or neutralizing MIP-2 could ameliorate HMGB1 expression and release of other pro-inflammatory cytokines. In present study, siRNA targeting MIP-2 was used to specifically knock down mip-2 mRNA, and an anti-MIP-2 antibody was applied to neutralize the MIP-2 protein. The levels of pro-inflammatory cytokines and HMGB1 were then measured. The aims this study were to investigate the role of MIP-2 in inflammation induced by LPS in vitro and to determine the possibility of blocking the HMGB1 signalling pathway by MIP-2 inhibition using mip-2 siRNA or an anti-MIP-2 antibody.
Gene silencing of murine mip-2 mRNA A specific siRNA targeting the murine mip-2 mRNA and universal negative mismatched control scramble siRNA were obtained from RiboBio (Guangzhou, China); their sequences are as follows: duplex# 1AACGAUUCGCUAAUUCACUGU; duplex# 2AAGCAGUCGGAUGGCUUUCAU". RAW264.7 cells were transfected with 25 nmol/ml annealed siRNA or control scramble siRNA in serum-free Opti-MEM I medium using Lipofectamine 3000 reagent (Invitrogen) as the transfection reagent according to the manufacturer's instruction. At 24 h after transfection, the RAW 264.7 cells were exposed to LPS for 24 h. HMGB1 was detected using an ELISA kit (Cloud Clone Corp, Houston, TX) for the following groups: (1) normal control, rMIP-2 (30 ng/ml); (2) normal control, LPS (0.25 µg/ml), LPS+ MIP-2 antibody (0.25 µg/ml LPS plus 1.0 µg/ml MIP-2 antibody), LPS+IgG (0.25 µg/ml LPS plus 1.0 µg/ml IgG), LPS+rMIP-2 (0.25 µg/ml LPS plus 30 ng/ml rMIP-2).
Detection of IL-6, TNF-α, IL-1β and HMGB1 protein expression using ELISA
The exposure time for RAW 264.7 cells was 2 h or 24 h, 100 μl of culture supernatant or reagent diluent standard were added to each well. ELISA kits for IL-1β, TNF-α and IL-6 (Dakewe Biotech Company Limited, Beijing, China) were used for detection. Absorbance was measured at 450 nm using a microtitre plate reader (Bio-Rad, Hercules, CA) [24] , and protein levels were calculated on the basis of standard curves. MIP-2 protein levels in culture supernatants were measured using rat MIP-2 ELISA kits (RayBiotech, Inc., Norcross, GA).
Measuring the mRNA expression levels of HMGB1, IL-1β, IL-6, mip-2, TNF-α, iNOS, Ccl-2 and TLR-4 using qRT-PCR Cells used for detecting mip-2 were divided into the following groups: normal control, LPS (0.25 µg/ ml), LPS+mip-2 siRNA (0.25 µg/ml LPS plus 25 nmol/ml mip-2 siRNA) and LPS+scramble siRNA (0.25 µg/ ml LPS plus 25 nmol/ml scramble siRNA).
Cells used for detecting HMGB1, IL-1β, IL-6, TNF-α, iNOS, Ccl-2 and TLR-4 were divided into the following groups: (1) normal control, (2) LPS+mip-2 siRNA (0.25 µg/ml LPS plus 25 nmol/ml mip-2 siRNA) and (3) LPS+scramble siRNA (0.25 µg/ml LPS plus 25 nmol/ml scramble siRNA).
After incubation with LPS, total RNA was prepared from RAW264.7 cells using Trizol reagent (Invitrogen, Corp., Carlsbad, USA) [25, 26] . Quantitative determination of total RNA was conducted using the GeneQuant pro RNA/DNA Calculator spectrophotometer (Amersham Biosciences, Freiburg, Germany). Total RNA (100 ng) was reverse transcribed using PrimeScript TM RT reagent Kit with gDNA Eraser (Code no. RR047A, Takara).
β-actin was used for normalization of the total mRNA input and the efficiency of cDNA synthesis [27] . qRT-PCR was performed using aliquots of cDNA with SYBR Premix EX Taq TM II (Code. no. RR820A, Takara) and an ABI Prism 7900 (Applied Bio systems, Foster, CA, USA). The primers used, listed in Table 1 , were obtained from Sangon Biotech (Shanghai).
Western blot assay
Cells used for determining HMGB1 protein levels were divided into the following groups: (1) normal control, LPS (0.25 µg/ml for 24 h), LPS+mip-2 siRNA (0.25 µg/ml LPS plus 25 nmol/ml mip-2 siRNA), LPS+scramble siRNA (0.25 µg/ml LPS plus 25 nmol/ml scramble siRNA); (2) for RAW264.7 cells: normal control, LPS (0.25 µg/ml), LPS+ MIP-2 antibody (0.25 µg/ml plus 0.25, 0.5 and 1.0 µg/ml MIP-2 antibody) and LPS+IgG (0.25 µg/ml plus 1.0 µg/ml IgG); for U937 or TPH-1 cells: normal control, LPS (0.25 µg/ml), LPS+ MIP-2 antibody (0.25 µg/ml plus 1.0 µg/ml MIP-2 antibody) and LPS+IgG (0.25 µg/ml plus 1.0 µg/ ml IgG); (3) normal control, rMIP-2 (30 ng/ml), rMIP-2+ MIP-2 antibody (30 ng/ml rMIP-2 plus 1.0 µg/ ml MIP-2 antibody), rMIP-2+IgG (30 ng/ml rMIP-2 plus 1.0 µg/ml IgG); (4) RAW264.7 cells were exposed to LPS plus 0.25, 0.5 and 1.0 µg/ml anti-MIP-2 antibody for 24 h; RAW264.7 cells were also treated with mip-2 mRNA siRNA for 24 h and then exposed to LPS for 24 h. U937 cells and THP-1 cells were exposed to LPS plus 1.0 µg/ml anti-MIP-2 antibody for 24 h. RAW264.7 cells were lysed with RIPA buffer (Millipore, Germany) to prepare total protein samples, and cytoplasmic and nuclear extracts from RAW 264.7 cells were extracted using Nuclear and Cytoplasmic Extraction Reagents (Product No.78835, Thermo Scientific, Rockford, USA). Total protein was used to assess HMGB1 levels by western blotting.
Cells were simultaneously exposed to 1.0 µg/ml anti-MIP-2 antibody and LPS for 24 h, and the collected total protein was used for western blot detection of proteins in different signalling pathways. Cells were also treated with different signalling pathway inhibitors for 2 h and then exposed to LPS for 24 h; HMGB1 levels in the collected total protein were measured by western blot assay.
After measurement of total, cytoplasmic and nuclear protein concentrations, 20 µg cellular protein was separated by 12% SDS-PAGE and transferred to a polyvinylidene difluoride membrane (Millipore, Billerica, MA). Each membrane was blocked in TBST containing 5% non-fat milk and incubated overnight, [28] .
Statistical analysis
All experiments were repeated at least three times. Differences between groups were analysed with Student's t-test. SPSS 17.0 software was used for statistical analysis.
Results

The inhibitory effects of mip-2 siRNA on the mRNA expression levels of mip-2, TNF-α, IL-1β, IL-6, Ccl-2, TLR-4, and iNOS in Raw264.7 cells exposed to 0.25 µg/ml LPS for 2 h
When RAW264.7 cells were exposed to 0.25 µg/ml LPS for 2 h, the mRNA expression levels of mip-2, TNF-α, IL-1β, IL-6, Ccl-2, TLR-4, and iNOS in the mip-2-siRNA group significantly decreased compared with the scramble siRNA control group, P<0.01. The results are shown in Fig. 1 and 2 .
Inhibitory effects of mip-2 siRNA on MIP-2, TNF-α, IL-1β and IL-6 secretion by RAW264.7 cells exposed to 0.25 µg/ml LPS for 2 h
The supernatant MIP-2, TNF-α, IL-1β and IL-6 protein levels of the 25 nM mip-2-siRNA groups were significant higher than those of all corresponding control groups (P<0.01), though the levels were still lower than all corresponding control siRNA groups (P<0.05 or P<0.01). These results are indicated in Table 2 . 
The effects of the MIP-2 antibody and rMIP-2 on the expression levels of TNF-α, IL-1β and IL-6 proteins in the supernatant of RAW264.7 cells exposed to LPS
The results (Fig. 3A-C) showed significantly reduced protein levels of proinflammatory cytokines IL-1β, TNF-α and IL-6 in the MIP-2 antibody group, whereas these levels were significantly enhanced in the rMIP-2 (with LPS) group compared with the LPS alone group (P<0.01). However, there were no significant differences in IL-1β, TNF-α and IL-6 protein levels between the LPS and IgG (Isotype control) groups (P>0.05). Fig. 3D -F illustrates significant differences in IL-1β, TNF-α and IL-6 protein The results of western blot assay showed significantly lower levels of HMGB1 protein expression in RAW264.7 cells (Fig. 4C ) of the 0.5 μg and 1.0 μg anti-MIP-2 antibody groups exposed to LPS compared to the LPS alone group (P<0.05 or P<0.01). Furthermore, in U937 (Fig. 4D) or THP-1 (Fig. 4E ) cells exposed to LPS, the level of HMGB1 protein expression in the 1.0 μg anti-MIP-2 antibody group was significantly lower than that in the LPS group (P<0.01). 
The effects of the MIP-2 antibody and rMIP-2 on the levels of HMGB1 protein expression in RAW264.7 cell cultures
The ELISA results (Fig. 5A ) indicated that the HMGB1 protein expression level in the supernatant of RAW264.7 cells exposed to LPS in the MIP-2 antibody group was significantly lower than that in the LPS group but was significantly higher in the rMIP-2 group than in the LPS group (P<0.01). Fig. 5B shows that the HMGB1 protein expression level in the supernatant of RAW264.7 cells not exposed to LPS in the rMIP-2 group was significantly higher than that in the NC group (P<0.01). Furthermore, the results of western blot assay (Fig. 5C ) revealed that that the HMGB1 protein expression level in RAW264.7 cells not exposed to LPS in the MIP-2 antibody group was significantly lower than that in the rMIP-2 group (P<0.05). In contrast, there was no significant difference in HMGB1 protein expression level between the rMIP-2 and IgG groups (P>0.05). 
The effects of 1.0 μg MIP-2 antibody on levels of phosphorylated PI3K/Akt, JAK/STAT3 and MAPK proteins in RAW264.7 cells exposed to LPS
As shown in Fig. 6 , the levels of Akt1/2/3, STAT3 and P38 protein phosphorylation in the 1.0 μg MIP-2 antibody group were significantly lower than those in the LPS group (P<0.05 or P<0.01). There were no significant differences in phosphorylated protein levels for Akt1/2/3, STAT3 and P38 between the IgG and LPS groups (P>0.05). All protein levels were detected by western blot assay.
The effects of inhibitors on levels of TNF-α, IL-1β, IL-6 and HMGB1 protein expression in RAW264.7 cell cultures exposed to LPS
The ELISA results of culture supernatants showed that the protein expression levels of IL-1β, TNF-α and IL-6 in the LPS alone group were significantly increased (P<0.01), but LY294002, AG490, SB203580, PD98059 or SP600125 treatment in the absence of LPS had no significant impact on the expression levels compared with the NC group (P>0.05, Fig.  7A-C) . In the culture supernatants of cells exposed to LPS, the ELISA results showed that the protein expression levels of IL-1β in the LY294002, AG490, SB203580, PD98059 and SP600125 groups were significantly reduced; the protein expression levels of TNF-α in the LY294002, AG490 and SB203580 groups were significantly decreased; and the protein expression levels of IL-6 in the LY294002, AG490 and SP600125 groups were significantly reduced compared with the LPS alone group (P<0.05 or P<0.01, Fig. 7D-F) . The results of the western blot assay showed that the protein expression levels of HMGB1 in the LPS group were significantly increased (P<0.01, Fig. 7G ) but that the levels in cells treated with AG490, SB203580, LY294002 or AG490+SB203580+LY294002 in the absence of LPS did not significantly change compared with those in the NC group (P>0.05, Fig. 7G ). In cells co-treated with LPS and other compounds, the western blot results exhibited that the protein expression levels of HMGB1 in the AG490, SB203580, LY294002 and AG490+SB203580+LY294002 groups were significantly reduced compared with the LPS alone group (P<0.05 or P<0.01, Fig. 7H ).
MIP-2 antibody (1.0 μg) inhibits the LPS-induced release of IκB and nuclear translocation of NF-κB p65 in RAW264.7 cells
The data shown in Fig. 8 illustrate that IκB protein expression (Fig. 8A ) and the concentration of NF-κB p65 in the cytoplasm (Fig. 8C ) of in RAW264.7 macrophages decreased significantly after LPS treatment (P<0.01), and this decline was significantly inhibited by the MIP-2 antibody (P<0.01). Moreover, the amount of NF-κB p65 in the nucleus (Fig. 8B ) was significantly increased (P<0.01) after exposure to LPS, which was also significantly inhibited by the MIP-2 antibody (P<0.01). These results indicate that the MIP-2 antibody can significantly inhibit the nuclear translocation of NF-κB p65 and significantly increase the concentration of cytoplasmic NF-κB p65 in macrophages stimulated by LPS. All protein levels were detected by western blot assay.
The effects of EP and MIP-2 antibody on the protein expression levels of TNF-α, IL-1β and IL-6 in the supernatant of RAW264.7 cells exposed to LPS
The ELISA results of the supernatants from cells exposed to LPS showed that the protein expression levels of TNF-α and IL-1β in the 18, 24 and 30 h EP groups were significantly decreased and that the protein expression levels of IL-6 in the 12, 18, 24 and 30 h EP groups were significantly reduced compared with the LPS alone group (P<0.05 or P<0.01, Fig. 9A-C) . Fig. 9D-F illustrates that the protein expression levels of TNF-α and IL-1β in the 6, 8, 10 and 12 h MIP-2 antibody groups were significantly reduced and that the protein expression levels of IL-6 in the 4, 6, 8, 10 and 12 h MIP-2 antibody groups were significantly diminished compared with the LPS alone group (P<0.05 or P<0.01). 
Discussion
Enhanced expression levels of MIP-2, HMGB1, proteins of different signalling pathways and cytokines in macrophage cells exposed to LPS
MIP-2 was initially identified in macrophage cells exposed to LPS. The infiltration of neutrophils from bone marrow to blood requires MIP-2 [29, 30] . Kopydlowski found that MIP-2 mRNA expression of peritoneal macrophages reached peak levels (15-60 folds) at 1-2 h after exposure to LPS in C3H/OuJ mice [31] . HMGB1 is a critical mediator of many fatal inflammatory responses [32] [33] [34] . It is well known that when cells are exposed to LPS, HMGB1 from damaged host cells interacts with receptors (such as RAGE, TLR-9 and TLR-4) on the cell surface, potently activating a wide range of inflammatory responses (production of cytokines), resulting in tissue damage [35, 36] .
The present investigation showed that after RAW264.7 cells were exposed to LPS, mip-2 mRNA and MIP-2 protein expression increased and that the expression levels of the proinflammatory cytokine HMGB1 (or HMGB1 mRNA) as well as other proteins (p-Akt, p-38, p-JNK, p-ERK and p-STAT3) increased significantly. We also explored cytoplasmic levels of IκB and nuclear translocation of NF-κB p65. The results showed that IκB protein expression decreased significantly after LPS treatment in RAW264.7 macrophages and that the amount of NF-κB p65 in the nucleus increased significantly while the concentration of NF-κB p65 in the cytoplasm significantly decreased after exposure to LPS. The results reveal that LPS can increase the translocation of NF-κB p65 from the cytoplasm to the nucleus. mRNA or protein expression of other cytokines (IL-6, TNF-α, IL-1β, Ccl-2, TLR-4, iNOS) was also significantly enhanced at 2 h or 24 h after exposure to LPS. Moreover, the expression levels of HMGB1 protein in U937 cells and THP-1cells increased after exposure to LPS. Our results indicated that RAW264.7 cells, U937 cells and THP-1 cells exposed to LPS exhibited a significant response.
Inhibition of MIP-2 can reduce the expression levels of MIP-2, HMGB1, proteins in different signalling pathways and cytokines in RAW264.7 cells exposed to LPS
Exposed to LPS, which is recognized by TLR-4, leads to activation of MyD88-dependent signalling pathways, including those involving mitogen-activated protein kinases (MAPKs), JAKs/STATs and PI3K/Akts. These signalling pathways produce pro-inflammatory cytokines via p38, JNKs, ERKs, and IKK protein kinase cascades, leading to activation of transcription factors such as NF-κB, AP-1 and IRF3, which promote expression of cytokine-encoding genes. Therefore, LPS-mediated production of cytokines (IL-6, TNF-α, IL-1β, MCP-1, IFN-β) in RAW264.7 cells occurs via PI3K/Akt, MAPK, JAK/STAT pathways [37] [38] [39] [40] [41] [42] .
Many synthetic drugs, natural products, and antibodies have been developed for suppressing HMGB1, TNF-α, IL-1β, and IL-6 release and NO production, and it was found that Res can inhibit expression of HMGB1 in cells exposed to LPS [43] [44] [45] [46] [47] [48] [49] [50] . Considering that MIP-2 expression is closely associated with the development of inflammatory responses in RAW264.7 cells exposed to LPS, we assessed the expression levels of HMGB1, proteins of different signalling pathways and cytokines after RAW264.7 cell exposure to LPS or rMIP-2 after suppressing MIP-2 expression to confirm the role of MIP-2 in inflammation induced by LPS or rMIP-2. An anti-MIP-2 antibody and siRNA against mip-2 were used to inhibit MIP-2 expression in RAW264.7 cells exposed to LPS. Not only were MIP-2 expression levels significantly reduced, but the expression levels of HMGB1, different signalling pathway proteins (p-Akts, p-38, and p-STAT3), and cytokines (IL-1β, IL-6 and TNF-α) as well as translocation of NF-κB p65 from the cytoplasm to nucleus (Fig. 8) were significantly decreased compared with cells only exposed to LPS. Table 2 shows that silencing expression of MIP-2 had a strong inhibitory effect on that of IL-6. In contrast, the effect on TNF-α and IL-1β expression was moderate. This may be because IL-6 expression increased significantly when the cells were exposed to rMIP-2 ( Fig. 3D-F ) compared with TNF-α/ IL-1β; thus, compared with TNF-α/ IL-1β, IL-6 expression declined significantly when the cells were exposed to mip-2 siRNA.
Our results suggested that MIP-2 may control HMGB1 and signalling pathways and that MIP-2 may play an important role in inflammatory response in RAW264.7 cells or other macrophages (U937 cells and THP-1 cells) exposed to LPS.
MIP-2 may serve as the target for treating inflammation
When HMGB1 was silenced in mice using siRNA, fewer pro-inflammatory cytokines were observed compared with the levels in control mice; HMGB1 knockdown also decreased the mRNA and protein levels of IL-1β, MIP-2, CXCL12 and CXCR4 in mice and in mononuclear cells [51] . Moreover, neutralization of HMGB1 with an anti-HMGB1 monoclonal antibody strongly inhibited Fas-induced production of MIP-2 and pro-inflammatory cytokines [52] . HMGB1 isolated from cells cultured in the presence of IL-1β, IFN-γ and TNF-α exerted enhanced pro-inflammatory activity, resulting in increased production of MIP-2 and TNF-α [53] . Therefore, up-regulation of this alarmin could be used to prevent or slow the inflammatory process. MIP-2 is mainly derived from macrophages [14, 54] ; thus, to determine whether LPS-induced MIP-2 production could exert a pro-secretory effect on the expression of HMGB1 and other pro-inflammatory cytokines and whether MIP-2 is a key upstream molecular switch for HMGB1 in RAW264.7 cells, we added rMIP-2 to RAW264.7 cells exposed to LPS. It was observed that rMIP-2 up-regulated the production of some proinflammatory cytokines compared with the LPS alone group. Our results also indicated that rMIP-2 had an enhancing effect on the inflammatory response induced by LPS and could promote the release of HMGB1. Additionally, after adding either MIP-2 antibody or mip-2 siRNA to RAW264.7 cells exposed to LPS, expression of MIP-2, HMGB1 and other proinflammatory cytokines (protein or mRNA) was significantly reduced. The results of our study suggest that MIP-2 may act upstream of HMGB1 in LPS-induced RAW264.7 cells. Accordingly, suppression of mip-2 mRNA expression at an early inflammatory stage could be beneficial for controlling inflammation.
The present study reports that specific inhibitors of the p38-MAPK, JAK/STAT3 and PI3K/Akt signalling pathways did not affect the expression of pro-inflammatory cytokines or HMGB1 in RAW264.7 cells. However, in RAW264.7 cells exposed to LPS, those specific inhibitors did significantly reduce the secretion of pro-inflammatory cytokines and HMGB1. Yao, X., et al. reported that JNK and ERK phosphorylation were activated in LPS-treated RAW264.7 cells [55] ; however, when adding MIP-2 antibody to RAW264.7 cells exposed to LPS, the JNK and ERK expression levels did not significantly decrease but expression of pro-inflammatory cytokines and HMGB1 were significantly diminished. Our study indicated that phosphorylation of p38, STAT3 and Akt was inhibited by the MIP-2 antibody, suggesting that MIP-2 regulates HMGB1 expression not through the JNK and ERK signalling pathways but rather the p38-MAPK, JAK/STAT3 and PI3K/Akt signalling pathways.
NF-κB p65 plays a key regulatory role in the transcription of pro-inflammatory mediators in activated macrophages, including iNOS, IL-1β, IL-6 and TNF-α [56] [57] [58] . Moreover, NF-κB p65 signalling is also responsible for HMGB1 expression [59] . Under normal conditions, NF-κB p65 is bound to IκB (its endogenous inhibitor) in the cytoplasm, but upon LPS stimulation, IκB dissociates from the NF-κB-IκB complex and is degraded. This allows the translocation of NF-κB p65 to the nucleus to activate target genes [60] [61] [62] . It has been suggested that inhibition of NF-κB p65 activity would reduce the production of proinflammatory cytokines. Therefore, in this study, we examined the effects of the MIP-2 antibody on IκB degradation and nuclear translocation of NF-κB p65 in LPS-stimulated RAW264.7 macrophages. The results showed that LPS-induced IκB degradation and nuclear translocation of NF-κB p65 were significantly reduced by the MIP-2 antibody in LPS-treated RAW264.7 macrophages.
The mechanisms of HMGB1 inhibition by EP have been reported. EP can inhibit HMGB1 acetylation in RAW264.7cells exposed to LPS [63] , mediate HMGB1 reduction by altering NF-κB DNA-binding activity [64] , and specifically inhibit HMGB1 release by inhibiting activation of p38-MAPK or NF-κB pathways [32] .
As stated above, MIP-2 could regulate the inflammation response in macrophages (RAW264.7 cells, U937 and THP-1 cells) exposed to LPS by up-regulating HMGB1. In addition, the MIP-2 antibody and mip-2 siRNA might significantly reduce expression of MIP-2, HMGB1 and other pro-inflammatory cytokine proteins or mRNA in vitro. Thus, MIP-2 may serve as a target for treating inflammation.
